- Nuvectis Pharma reported **cash and cash equivalents of $35.4 million** as of September 30, 2025, an increase from $18.5 million at December 31, 2024, primarily due to a public offering and At-the-Market facility utilization.  **[1875558_fcd11d05a39249868558f13cb761fa1d_1]** **[1875558_fcd11d05a39249868558f13cb761fa1d_4]** 
- The company's **net loss was $7.5 million** for the three months ended September 30, 2025, an increase from $4.2 million for the same period in 2024, largely due to a $2.0 million milestone achievement expense and $0.7 million for a clinical drug-drug interaction study.  **[1875558_fcd11d05a39249868558f13cb761fa1d_1]** **[1875558_fcd11d05a39249868558f13cb761fa1d_4]** 
- **Research and development expenses** for the third quarter of 2025 were **$5.8 million**, compared to $2.8 million for the third quarter of 2024.  **[1875558_fcd11d05a39249868558f13cb761fa1d_1]** **[1875558_fcd11d05a39249868558f13cb761fa1d_4]** 
- The **NXP900 Phase 1b program was initiated**, with the single agent study underway and the combination portion expected by year-end, following the successful completion of the Phase 1a dose escalation study and a clinical drug-drug interaction study.  **[1875558_fcd11d05a39249868558f13cb761fa1d_0]** **[1875558_fcd11d05a39249868558f13cb761fa1d_1]** 
- Nuvectis Pharma expects its **cash runway to support the company's operations into Q3 2027**.  **[1875558_fcd11d05a39249868558f13cb761fa1d_0]**

Nuvectis Pharma Reports Third Quarter 2025 Financial Results and Business Highlights

- Nuvectis Pharma reported a **net loss of $7.5 million** for the third quarter of 2025, an increase from $4.2 million in the prior year period, primarily due to a **$2.0 million milestone achievement expense for NXP900** and **$0.7 million related to the clinical drug-drug interaction study**.  **[1875558_0001104659-25-105953_tm2530070d1_ex99-1.htm:0]** **[1875558_0001104659-25-105953_tm2530070d1_ex99-1.htm:2]** 
- **Research and development expenses increased to $5.8 million** for the three months ended September 30, 2025, up from $2.8 million in the same period of 2024, while **general and administrative expenses rose to $2.0 million** from $1.5 million.  **[1875558_0001104659-25-105953_tm2530070d1_ex99-1.htm:0]** **[1875558_0001104659-25-105953_tm2530070d1_ex99-1.htm:1]** **[1875558_0001104659-25-105953_tm2530070d1_ex99-1.htm:2]** 
- The company's **cash and cash equivalents stood at $35.4 million as of September 30, 2025**, a significant increase from $18.5 million as of December 31, 2024, with a **cash runway expected to support operations into Q3 2027**.  **[1875558_0001104659-25-105953_tm2530070d1_ex99-1.htm:0]** **[1875558_0001104659-25-105953_tm2530070d1_ex99-1.htm:2]** 
- Nuvectis initiated the **NXP900 Phase 1b program**, successfully completed the **NXP900 Phase 1a dose escalation study**, and finished a **clinical drug-drug interaction study** for NXP900.  **[1875558_0001104659-25-105953_tm2530070d1_ex99-1.htm:0]**

Nuvectis Pharma Reports Q3 2025 Financial Results and NXP900 Program Updates

- Nuvectis Pharma reported a **net loss of $7.5 million** for the three months ended September 30, 2025, an increase from $4.2 million in the same period of 2024, primarily due to a **$2.0 million milestone achievement expense** for NXP900.  **[1875558_902dc9b7838f4cf4be67988375577042_1]** 
- As of September 30, 2025, **cash and cash equivalents were $35.4 million**, compared to $18.5 million as of December 31, 2024, primarily due to a public offering and At-the-Market facility utilization.  **[1875558_902dc9b7838f4cf4be67988375577042_1]** 
- The company initiated the **NXP900 Phase 1b program**, with the single-agent study underway and the combination portion expected by year-end, following the successful completion of the Phase 1a dose escalation study.  **[1875558_902dc9b7838f4cf4be67988375577042_0]** **[1875558_902dc9b7838f4cf4be67988375577042_1]** 
- Nuvectis Pharma expects its **cash runway to support operations into Q3 2027**.  **[1875558_902dc9b7838f4cf4be67988375577042_0]**

Nuvectis Pharma (NVCT)